A Phase 2 interventional study of NNC 0142-0000-0002 and Placebo in Inflammation and Crohn's Disease, sponsored by Janssen Research & Development, LLC. Completed at 23 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-01.
Sponsored by Janssen Research & Development, LLC · Phase 2, Interventional, and Treatment
This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 78 is above the median of 66 across 1,188 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.
Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: NNC 0142-0000-0002
Drug: Placebo
A single dose administered subcutaneously (s.c., under the skin)
A single dose administered subcutaneously (s.c., under the skin)
Change in disease activity assessed by CDAI (Crohn's disease activity index)
Time frame: From baseline to week 4
Number of adverse events (AEs)
Time frame: From baseline to weeks 12 and 24
Immunogenicity of NNC 142-0002
Time frame: At week 24
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC